Drugs / MVA-EbolaZ
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02368119 | Mar 2015 → Sep 2016 | Ebola hemorrhagic fever | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 1 | NCT02354404 | Jan 2015 → Apr 2017 | Ebola hemorrhagic fever | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MVA-EbolaZ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02368119 ↗ |
| Modality | Vaccine | “IM injection of MVA-EbolaZ vaccine” NCT02368119 ↗ |
| Route | Intramuscular | “IM injection of MVA-EbolaZ vaccine” NCT02368119 ↗ |